The transfer of the Glial cell line-derived neurotrophic factor (GDNF) gene to the central nervous system by a recombinant adenoviral vector (Ad) was studied. We constructed the adenovirus vector Ad-NSE-GDNF from which the E1, E3/E4 regions of Ad5 have been deleted and in which the GDNF gene was under the control of a neuron-specific enolase (NSE) promoter. The vector was injected into the striatum of a rat model of Parkinson's disease. We found that (i) the NSE promoter can restrict transgene expression in neurons; (ii) Ad-NSE-GDNF significantly protected dopaminergic (DA) neurons in the substantia nigra (SN) but did not reverse the impairments of amphetamine-induced rotational behavior in lesioned rats.
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder characterized by impairment of motor function caused by loss of dopaminergic (DA) neurons from the substantia nigra (SN). The degeneration of nigral DA neurons is slow and progressive. As the disease progresses, patients become less responsive to the currently used treatment (administration of L-3,4 (OH) 2 phenylalanine (Dopa)). Various possible methods to halt the continuous loss of DA neurons have, therefore, been studied: one involves the administration of glial cell linederived neurotrophic factor (GDNF).
GDNF is a member of the transforming growth factor beta superfamily, which together with neurturin, artemin and persephin forms the GDNF family ligands.
1 GDNF was first discovered by Lin et al. 2 and promote the survival of DA neurons in vitro. The effects of GDNF have been studied in animal models of PD. Administered into the striatum or in the substantia nigra (SN) of rats, [3] [4] [5] GDNF has a neuroprotective effects for DA neurons after striatal lesions. In a primate model of PD, intracerebral injection of GDNF is followed by improved motor function. 6 These results in animal models led to clinical trials in humans. Recently, Gill et al., 7 and Love et al., 8 reported therapeutical effects of GDNF for PD patients in phase 1 clinical trials involving continuous pump-driven infusion of GDNF into the putamen. The inconvenience of this strategy for delivering GDNF continuously and long term into the brain (for a review, see Kirik et al. 9 ) led to the use of viral vectors containing therapeutic transgenes. Injection of the first generation of adenoviral, adeno-associated viral (AAV) or lentiviral vectors bearing the GDNF gene into the striatum or the substantia nigra [10] [11] [12] [13] [14] [15] [16] [17] is neuroprotective, induces fiber outgrowth and improves motor function. These vectors transduce both neuronal and non-neuronal cell populations in the target area. However, the contributions of the various different cell populations to the protection of nigral neurons and to the improvement of clinical symptoms of PD are not clear. Using a glial-specific promoter to restrict the GDNF expression to astrocytes, we demonstrated the partial protection of nigral neurons after striatal lesions. 18 It is now important to determine whether the introduction of the GDNF gene directly into neurons has similar effects.
The aim of this study was to quantify the survival of DA neurons and the consequences of survival on the amphetamine-induced rotational behavior after injection of a defective adenoviral vector (Ad) carrying the GDNF gene under the control of a neuron-specific enolase (NSE) promoter into the striatum of a rat model of PD. 19 The recombinant adenoviral vector Ad-NSE-GDNF was constructed using a defective E1, E3/E4 adenovirus. 20 This defective adenovirus is less toxic than earlier adenoviral vectors and provokes less inflammation in the host animals. 18, 20 We report that the GDNF transgene was expressed in neurons of the transduced striatum in PD rats treated with Ad-NSE-GDNF. In the SN, about 60-64% of the DA neurons remained at three time points analyzed, whereas only 40-42% remained in the empty-Ad (EP)-treated PD rats and in rats lesioned only by 6-hydroxydopamine (6-OHDA). The GDNF released by the transduced neurons did not reverse the impairments of the amphetamineinduced rotational behavior of treated animals.
Results
We used an E1,E3/E4-defective adenovirus encoding GDNF under the control of a neuronal-specific promoter, NSE. This defective adenovirus has a large deletion in the E4 region that abolishes the synthesis of all E4-encoded gene products. 20 We investigated the effect of the overexpression of GDNF in the striatum on protection of DA neurons and on the amphetamine-induced rotation in a rat model of PD, using the experimental paradigm shown in Figure 1 .
In vitro experiments
We first tested whether the recombinant Ad-NSE-GDNF was able to express GDNF in primary cultures of mesencephalic cells and astrocytes. The GDNF produced and released by the transduced cells was quantified using ELISA. We found higher levels of GDNF in the medium and in the cellular pellets of astrocytes than in the mesencephalic cells (Table 1 21 We determined DA neurons survival by directly counting under the microscope the tyrosine hydroxylase (TH)-positive neurons. The number of TH-positive neurons in mesencephalic cultures treated with Ad-NSE-GDNF was 1.7 times higher (1505 neurons789; P ¼ 0.0063 treated versus control) than in the non-infected control cells (911 neurons769). Thus, the Ad-NSE-GDNF vectors contribute to the survival of DA neurons in vitro.
In vivo experiments GDNF expression in intact animals. In preliminary experiments, various doses of Ad-NSE-GDNF (10   7   , 10   8   ,  10 9 virus particles (vp)/rat) were injected into the striatum of intact rats to determine the dose giving optimal GDNF expression. Animals were killed 10 days, and 4, 6 and 12 weeks after viral administration, and GDNF expression was assessed by enzyme-linked immunosorbent assay (ELISA). The dose of 10 8 vp/rat gave higher GDNF expression at all three times analyzed than the other doses ( GDNF expression in the striatum and in the SN of lesioned animals. We quantified the GDNF levels and relative viral DNA levels in the striatum by ELISA and by sqc-PCR 1 week after injection of Ad-NSE-GDNF into the striatum (str, six sites). We found 12207430 pg/str ( Figure 2 ) of GDNF and 3 Â 10
À3
70.5 ng (Figure 3 ) of viral DNA in the injected striatum. The rats were then lesioned with 6-OHDA and killed 4, 6 and 12 weeks after viral treatment.
The amount of GDNF, as measured by ELISA, remained unchanged, about 13007467 pg/str, between 4 and 6 weeks after injection of Ad-NSE-GDNF (NSE group) into the striatum of lesioned rats (Figure 2 ). This Figure 1 Time course of surgery and analysis. The animals received Ad-NSE-GDNF (10 8 vp/rat) and empty-adenovirus (10 8 vp/rat) 1 week before the 6-OHDA lesion. Amphetamineinduced rotation (AR) was tested at 3, 4, 6 and 12 weeks (after lesion). Fluorogold (FG) was injected in the striatum at 3, 5 and 11 weeks, whereas AAV-CMV-GFP was injected in the SN at 2 and 8 weeks after viral treatment. The animals were killed at 4, 6 and 12 weeks for biochemical (ELISA test and sqc-PCR) and morphological analysis (MA). Abbreviation: GDNF, Glial cell line-derived neurotrophic factor. GDNF levels (pg/ml) measured in the medium and cellular pellets of mesencephalic cells and cultured astrocytes 4 days after infection with Ad-NSE-GDNF (500 vp/cell). Noninfected cells were used as controls. Neuronal expression of GDNF in a rat model of PD NA Do Thi et al amount of GDNF was similar to the GDNF quantity obtained before the 6-OHDA lesion (1 week, Figure 2 ). The concentration of GDNF then decreased between 6 and 12 weeks after treatment ( Figure 2 ). In control rats lesioned by 6-OHDA (OHDA group) or lesioned and treated with empty-Ad (EP group), the amount of GDNF in the striatum were five to seven times lower than that in Ad-NSE-GDNF-treated rats (Figure 2 ) at the three time points. We determined whether the decrease in GDNF levels between 6 and 12 weeks in the Ad-NSE-GDNFinjected striatum was due to a loss of the transduced cells or due to a downregulation of NSE promoter. The relative amount of viral DNA in the striatum as estimated by sqc-PCR remained unchanged from 1 week (which was before the lesion) to 12 weeks after the viral treatment ( Figure 3) . Thus, the decrease in GDNF expression between weeks 6 and 12 was most probably owing to the NSE promoter being downregulated rather than owing to the loss of viral DNA. We checked that the GDNF detected by ELISA was expressed in neurons, by co-staining cryostat sections from the striatum close to the Ad-NSE-GDNF injection sites with anti-GDNF antibody and anti-NeuN antibody, a marker of mature neurons. Bound anti-GDNF 70.62 ng after 6 weeks. By 12 weeks, the GDNF levels in the ipsilateral SN of Ad-NSE-GDNFtreated animals were similar to those in the contralateral SN and in the SN of OHDA and EP control rats, at about 46713 pg/SN.
Rotational behavior. In animals with a striatum unilaterally denervated by 6-OHDA, intraperitoneal injection of amphetamine induces a rotational behavior in the direction ipsilateral to the lesion. This rotation increases as striatal DA is depleted after the lesion. 22 In this work, we studied the amphetamine-induced rotational behaviour of the animals from 2 weeks after 6-OHDA lesion (3 weeks after Ad-NSE-GDNF treatment) to determine the consequences of GDNF delivery to the striatum by Ad-NSE-GDNF. The rotational response of the NSE group was the same as that of the control groups at all time points ( Figure 5 ). Only eight of the 60 animals (four at 6 weeks and four at 12 weeks after Ad-NSE-GDNF treatment) showed a reduced amphetamine-induced rotation. This absence of a reduction in amphetamineinduced rotation in rats treated with Ad-NSE-GDNF may be owing to decreased release of dopamine from preserved striatal fibers in the lesioned side. We tested Figure 4 Immunostaining of the striatum 6 weeks after viral treatment. Colocalization of anti-GDNF antibody (a) and anti-NeuN antibody (b) was observed, (c) merge of (a) and (b). Striatum section was double-stained with anti-GDNF antibody and anti-GFAP antibody. Astrocytes were not stained with anti-GDNF antibody (d), while they were stained with anti-GFAP antibody (e). Scale bar represents 70 mm.
Figure 2 GDNF levels measured by ELISA in the ipsilateral and contralateral striatum from Ad-NSE-GDNF-treated animals (NSE group) before (1 week) and after lesion (4, 6, 12 weeks) and from control animals (OHDA and EP groups, six animals per point). The amount of GDNF protein was higher in Ad-NSE-GDNF-treated animals than in the control animals at the three time points. (Po0.0001, P ¼ 0.0009, P ¼ 0.003, NSE versus OHDA group at 4, 6 and 12 weeks, respectively; Po0.0001, P ¼ 0.0006, P ¼ 0.001 NSE versus EP group at 4, 6 and 12 weeks respectively.) Figure 3 Levels of viral DNA in the transduced striatum of Ad-NSE-GDNF-treated animals. The relative level of viral DNA did not change from 1 to 12 weeks after viral injection (six animals per point; P ¼ 0.2, P ¼ 0.4, 4 versus 6 and 12 weeks, respectively; P ¼ 0.6, 6 weeks versus 12 weeks).
Neuronal expression of GDNF in a rat model of PD NA Do Thi et al this by quantifying nuclear Fos immunoreactivity in striatal neurons as an indirect measure of the release of dopamine. In normal rats, high doses of injected amphetamine increase the density of Fos-positive nuclei in the intact striatum. 23 This may be because amphetamine induces release of DA from nerve terminals via activation of the D1 receptor. 24, 25 In rat striatum lesioned with 6-OHDA, the density of Fos-positive nuclei is lower than normal and can be restored by intrastriatal transplants of DA tissue. [26] [27] [28] We tested whether Ad-NSE-GDNF affected the release of DA by striatal fibers by injecting control rats (OHDA, empty-Ad) and Ad-NSE-GDNF-treated rats with amphetamine (5 mg/kg, i.p.). We counted Fos-positive nuclei 2 h after drug administration in the lesioned and unlesioned striatum by examination of three sections containing the lesion and viral injection sites. The experiment was performed 4, 6 and 12 weeks after viral treatment (Figure 6a and b) . We found similar numbers of Fos-positive nuclei in the lesioned striatum (reported as percentages of the unlesioned side) in OHDA rats (60%710), empty-Ad control rats (57.5%77) and Ad-NSE-GDNF-treated rats (64%76) at the three time points (Figure 6a and b) . Thus, the 6-OHDA-induced decrease in the percentage of Fospositive nuclei (reflecting DA levels) was not reversed by GDNF production from Ad-NSE-GDNF.
Effects of Ad-NSE-GDNF on DA fibers in lesioned striatum. Injection of 6-OHDA into the striatum causes immediate toxic damage to the DA fibers followed by a rapid degeneration of their terminals. 5, 29 We used immunohistochemistry for the TH to assess the extent of denervation induced by intrastriatal 6-OHDA lesions (values reported are mean percentages of the values for the unlesioned, contralateral striatum at 4, 6 and 12 weeks). The percentages of DA fibers that were TH positive in the lesioned striatum, as measured by optical density, were 46%75 for the OHDA control group and 51%74 for the EP control group. In rats treated with Ad-NSE-GDNF, the density of TH-positive fiber innervation was similar to that measured in control rats (44%74 of the contralateral striatum) at three time points; Ad-NSE-GDNF did not therefore protect TH-positive fibers in lesioned striatum. There was no axonal sprouting in the lesioned striatum or in the globus pallidus of NSE animals.
Protection of DA neurons in the SN and maintenance of nigrostriatal connections. We evaluated nigral DA neuron protection on SN sections after staining the sections with an anti-TH antibody (see Materials and methods). In OHDA and empty-Ad control animals, the number of DA TH-positive neurons in the ipsilateral SN was about 40-42% of that in the intact side at 4, 6 and 12 weeks (Figure 7) . In animals treated intrastriatally with Figure 5 Amphetamine-induced rotanional behavior was similar in Ad-NSE-GDNF-treated (NSE, 20 animals per point) and control animals (OHDA and EP groups, 10 animals per point). (P ¼ 0.9, P ¼ 0.7 at 3 weeks; P ¼ 0.2, P ¼ 0.2 at 4 weeks; P ¼ 0.5, P ¼ 0.5 at 6 weeks; P ¼ 0.8, P ¼ 0.7 at 12 weeks, NSE versus OHDA and EP groups respectively.) Figure 6 Fos-staining of the striatum 6 weeks after Ad-NSE-GDNF injection. The number of Fos-positive nuclei was lower in the lesioned striatum (a) than in the contralateral side (b). Scale bar represents 100 mm. Ad-NSE-GDNF, we observed a significant neuroprotective effect on TH-positive neurons in the ipsilateral SN, with the number of TH-positive neurons being about 60-64% of the contralateral side at the three time points (Figure 7) . We tested whether the DA neuron protection was owing to the nigrostriatal pathway being 'maintained', by bilaterally injecting the retrograde tracer Fluorogold (FG) into the striatum of 6-OHDA-lesioned animals and Ad-NSE-GDNF-treated animals ( Figure 1, Figure 8a and b). The number of FG-positive cells in the SN was counted 1 week later to estimate the number of DA neurons that were still connected to the striatum. In the OHDA control group, the number of FG-positive cells in the ipsilateral SN was 3573.5% after 4 weeks, 3274% after 6 weeks and 3673% after 12 weeks of that in the contralateral side (Figure 8e and f) . By contrast, in Ad-NSE-GDNF-treated animals, the numbers of FG-positive cells in the ipsilateral SN were 5874, 5573 and 5776% of the intact side (Figure 8c and d) . Thus, in OHDA control rats, the number of TH-positive neurons in the ipsilateral SN (40-42%) was similar to that of FG-positive neurons (32-36%). In Ad-NSE-GDNF-treated animals, the number of TH-positive neurons (60-64%) was similar to that of FG-positive neurons (55-58%). We found similar correlations between the TH-positive and the FG-positive cells in the SN of OHDA control animals and Ad-NSE-GDNF-treated animals, suggesting that the axonal projections to the striatum of the remaining nigral neurons were generally preserved. We confirmed this by injecting adeno-associated vector (AAV)-green fluorescent protein (GFP), used as an anterograde tracer and which infects the nigral neurons, 14, 30 into the ipsilateral SN of Ad-NSE-GDNF-treated rats 1 month before they were killed (Figure 8g and h) . The GFP protein released by transduced nigral neurons in the SN (Figure 8h ) was transported anterogradely to the ipsilateral striatum (Figure 8g ). These results demonstrate a significant protection of DA neurons in the SN of Ad-NSE-GDNF-treated animals via the preserved nigrostriatal connections.
Inflammatory responses in the striatum. The inflammatory reaction in the striatum after viral treatment was analyzed by CD4/CD8 staining of sections. The number of animals which presented CD4 immunoreactive cells (+++) was higher in animals of the NSE group than in the control groups (OHDA and EP groups; Table 3, Figure 9c and d) after 4, 6 and 12 weeks. In these animals, CD4-positive cells were numerous at the injection sites ( Figure  9d ). They were also scattered throughout the parenchyma and close to the blood vessels. CD8-positive cells (Table  3 , Figure 9c ) were also seen around the injection sites. They were less numerous than CD4-positive cells. The intensity of GFAP immunostaining was greater than in the unlesioned striatum and showed dense network of 
Discussion
We analyzed the protection of DA neurons and the prevention of rotational behavior provided by the overexpression of GDNF in neurons of the striatum against a 6-OHDA lesion in a rat model of PD. Thus, we constructed a defective adenoviral vector in which the E1, E3/E4 regions of the Ad5 were deleted and in which the GDNF gene was under the control of the neuronalspecific promoter NSE.
We found that the Ad-NSE-GDNF vector expresses GDNF in striatal neurons of NSE rats following the stereotaxic injection of the Ad-vector. Under these conditions, between 60 and 64% of dopaminergic neurons were preserved after the 6-OHDA lesion. This DA cell protection in the SN may be owing to the GDNF produced and released in the striatum (B1300 pg/ striatum corresponding to B0.06 ng/mg of tissue), which is then retrogradely transported to the SN where it initially enhances the resistance of DA neurons to the 6-OHDA lesion. The retrograde transport of GDNF from the striatum to the SN has been demonstrated by Tomac et al. 31 The effect of GDNF may also result from the retrograde transport of the vector itself from the striatum to the SN where it can produce neurotrophic factor. The retrograde transport of Ad vectors from the striatum to the SN has been reported by Byrnes et al. 32 In our study, the levels of GDNF measured in the striatum were sufficient to protect DA neurons from the 6-OHDA lesion although they were lower than levels observed in other studies. 12, 14 The striatal injection of 6-OHDA rapidly destroys DA terminals in the striatum, and then causes progressive degeneration of DA neurons in the SN over several weeks. 19 Several studies have shown that GDNF delivered by an adenoviral or AAV vectors protect DA neurons and their nerve terminals in the striatum against 6-OHDA toxicity. 10, 14, 25 By contrast, we found that all rat groups showed about a 55% reduction in TH-immunoreactive fiber density versus the unlesioned side, suggesting that Ad-NSE-GDNF did not protect against DA nerve terminal degeneration and failed to induce sprouting of the remaining DA terminals in the lesioned striatum. A similar result has been reported in rat models of PD in which GDNF was administered into the SN before or after striatal lesions. 33, 34 The GDNF treatment in these studies did not restore DA innervation in the lesioned striatum although DA cells were protected.
The protection of DA innervation in the striatum is crucial for a positive behavioral outcome. 14, 34 In our experiments, the increase in rotational behavior in the Ad-NSE-GDNF-treated animals is consistent with the low level of striatal innervation. The lack of functional recovery in NSE rats suggests that there was no increase in DA release by preserved DA fibers in the lesioned striatum. This is supported by a decrease in the number of Fos-positive nuclei observed in the lesioned striatum of Ad-NSE-GDNF-treated animals. Several studies have reported that the improvement of the functional behavior reflects an increase in striatal DA release, 10, 25 as assessed by Fos immunostaining, 25 after injection of Ad-GDNF in the striatum. Thus, the absence of functional recovery in animals treated with Ad-NSE-GDNF is most likely owing to the reduced level of GDNF released in the lesioned striatum.
The low level of GDNF released in the striatum may be owing to the low efficiency of adenoviral vectors to transduce neurons. Consistent with this, we found that the number of neurons transduced by Ad-NSE-GDNF was low and thus, only a small amount of GDNF could be synthesized in the transduced striatum. The low number of GDNF-expressing neurons was not due to the low titer of the NSE-vector, as we obtained a similar Neuronal expression of GDNF in a rat model of PD NA Do Thi et al relative amount of viral DNA after injection of the Ad-GFAP-GDNF in our previous study. 18 By contrast, we found that by using Ad-GFAP-GDNF (10 8 vp/rat), which induces GDNF expression in astrocytes, 18 a relative 5 Â 10 À3 ng of viral DNA delivered between 70 and 75 ng/str of GDNF in the transduced striatum at 4 and 6 weeks. In the present study, we found that, by using the Ad-NSE-GDNF vector (10 8 vp/rat), which induces GDNF expression in neurons, a similar relative amount (B3 Â 10 À3 ng) of viral DNA delivered about 1.3 ng/str of GDNF in the striatum. This discrepancy between the high viral Ad-NSE-GDNF DNA concentration and low GDNF protein levels and the high Ad-GFAP-GDNF DNA concentration and high protein levels in astrocytes may be owing to the cellular machinery of neurons not adequate to produce and release GDNF. Thus, neurons are likely to produce and release less GDNF than glial cells.
We also studied the immune response of the animals to the adenoviral vectors. The first-generation adenovirus (E1 and E3-deleted adenoviral vectors) caused inflammation in the transduced striatum of treated animals 10, 12 compared to animals injected with 6-OHDA. In a previous study, 18 we used Ad-GFAP-GDNF in which the E1, E3/E4 regions of the Ad5 were deleted and found that the inflammation response of the animals decreased with respect to the first-generation adenovirus. The immune response in Ad-GFAP-GDNF-treated animals was similar than that observed in OHDA control rats. In the present study, we observed a slightly greater inflammation in NSE rats than in OHDA control rats and empty adenovirus-treated animals. As the vectors used have the same viral backbone, the cause of this different inflammatory response is unclear. It may result from the differential expressions of viral proteins in transduced cells owing to the presence of NSE promoter sequences that may interfere and increase the viral protein expression.
GDNF gene delivery in vivo can prevent the degeneration of nigral neurons and their processes and is a key approach for treating PD. However, the cellular targets of GDNF expression and the promoter activity of the vector may be critical factors. Our results demonstrate that neurons are less suitable target cells than glial cells to express GDNF. Astrocytes synthesize and release high levels of GDNF in the target area of the brain. 18 These cells can produce substantial amounts of trophic factors that protect neurons affected by the lesions. In addition, astrocytes provide a 'natural' site where several growth factors including GDNF [35] [36] [37] [38] are synthesized in specific areas and time points. Thus, astrocytes provide a most efficient target to express trophic factors in neurodegenerative diseases such as PD.
Materials and methods

Recombinant adenovirus
We constructed the recombinant Ad-NSE-GDNF (E1,E3/ E4-defective adenovirus) by homologous recombination, which was prepared as previously described. 18 Briefly, we used the NSE promoter. The pNSE-Ex4 plasmid was provided by Dr Sutcliff, Research Institute of Scripps Clinic, La Jolla, CA, USA. It contains 4 kb of rat NSE gene DNA with 2.8 kb of 5 0 flanking DNA, 50 bp of exon I (non-translated), 1.2 kb of intron I and 6 bp of exon II (with no AUG). The complementary DNA (cDNA) of the rat GDNF was amplified by reverse transcription-polymerase chain reaction (RT-PCR) from cultivated astrocytes as previously described. 10 We prepared the shuttle plasmid by introducing the expression cassette NSE-GDNF-poly A in plasmid pXL 3234, which contains Ad5-ITR-psi and pIX sequences. The shuttle plasmid was then introduced into Escherichia coli JM83 containing pXL 3412, 39 which underwent homologous recombination. Plasmid pXL3412 contains Ad5 deleted in the E1/E3/E4 regions. 20 After we had obtained the plasmid containing the recombinant adenoviral genome (RAG) bearing the GDNF transgene, we used the cesium chloride technique (maxiprep, Gibco BRL, Cergy-Pontoise, France) to prepare DNA from RAG. Viruses were generated by transfection of PacI-digested RAG-DNA into the packaging IGRP2 cells 40 using lipofectamine (Gibco, BRL). The titer of the Ad-NSE-GDNF viral stock was 6.2 Â 10 11 vp/ ml, determined as previously described. 41 The empty adenovirus, used as control and containing no promoter and no transgene, was the gift of Dr Ferrero L. The titer of the empty adenovirus was 10 12 vp/ml.
In vitro experiments
Mesencephalic cell cultures were prepared from rat embryos (Sprague-Dawley, E 14.5) as previously described. 10 The cells (10 5 cells) were plated on poly-lysinecoated 24-well plates. After 24 h, the cells were infected with Ad-NSE-GDNF (500 vp/cell) by incubation for 1 h at 371C. For each well, the medium (N 2 -supplemented Dulbecco's modified Eagle's medium (DMEM)/F12) and the cellular pellet were harvested 4 days after infection and analyzed for GDNF levels by ELISA (Promega, Madison, WI, USA), and for viral DNA levels. In some experiments, the mesencephalic cells were fixed with 4% paraformaldehyde. The cells were stained with polyclonal antibody against TH. The number of TH-positive neurons were counted directly under the microscope. We used six wells for each experiment and each experiment was repeated twice.
Astrocytes were prepared from the striatum of Sprague-Dawley rat embryos (E 15). Cells were cultivated in DMEM (Gibco) with 10% of fetal calf serum 42 (FCS). The cells were treated with trypsin 1 week after plating and seeded by differential adhesion on plastic dishes. After a further 2 weeks in DMEM+10% FCS, the astrocytes were treated with trypsin and seeded in 24-well plates (10 5 cells per well). Cultured astrocytes were infected with Ad-NSE-GDNF and analyzed as described for mesencephalic cells.
Surgical procedures
Ad-NSE-GDNF injections. We used 114 female Sprague-Dawley rats (200-220 g) in this study. The rats were anaesthetized (Rompun/Ketamine, v/v, 1 ml/kg), and injected stereotaxically with Ad-NSE-GDNF at a dose of 10 8 vp/rat, as previously described. 18 The Ad-NSE-GDNF vector and empty-Ad were diluted in 6 ml phosphate-buffered saline (PBS) and were introduced at 1 ml per site in the left striatum at the following coordinates: (1) 43 At 1 week after viral injection, 5 ml of 6-hydroxydopamine (6-OHDA) (Sigma-Aldrich, St Quentin Fallavier, France, 4 mg/ml in ice-cold ascorbate saline) was injected stereotaxically into the left striatum of animals at a flow rate of 0.5 ml/min at the following coordinates: AP: +1.2 mm from the bregma; L: +2.5 mm lateral to the midline; V: À5, 4.6 and 4.2 mm ventral to the dural surface, three-site lesion. 10 Rats were killed 4, 6 and 12 weeks after viral treatment.
Visualization of nigrostriatal projections. The connections between the striatum and the SN were detected using two methods. First, we injected a retrograde tracer, Fluorogold (FG, 2% in NaCl 0.9%, 0.3 ml per rat, Fluorochrome, LLC, Denver, CO, USA) bilaterally into the striatum, 1 week before the animals were killed (Figure 1) , at the same coordinates as the lesion (A ¼ 1.2 mm, L ¼ +2.5 mm/À2.5 mm, V ¼ À5 mm). Second, we injected a recombinant adeno-associated viral vector expressing GFP, rAAV-CMV-GFP (gift of Dr Moullier P, University of Nantes, France) unilaterally over the left SN 1 month before the animals were killed (Figure 1 ). We used this vector as an anterograde tracer as GFP was present in the transduced neurons and their projections. The high transduction efficency of the rAAV vector for DA neurons in the SN has been shown by Kirik et al.
14 The animals were injected with 2 ml of the vector (3.3 Â 10 11 infectious units/ml) at the following coordinates: AP ¼ À5.3, ML ¼ 1.9, DV ¼ À7.6/ 7.8 with the tooth bar set to 0. The injection flow rate was 0.25 ml/min.
Biochemical and molecular analysis
We used six rats from each group at each time point for the biochemical and molecular analysis.
Quantification of GDNF levels. Striatum and SN from injected rats were removed, frozen in nitrogen liquid, and stored at À801C for analysis of GDNF levels by ELISA using the GDNF Emax ImmunoAssay system (Promega, Madison, WI, USA). Tissues were homogenized in buffer (Tropix) at a tissue concentration of 40 mg/ml (wet weight) in ethylene diamine tetra acetate (EDTA)-free protease inhibitor cocktail (Roche, Meylan, France). We used 50 ml of the buffer for cellular pellets. After centrifugation (5000 g, at 41C for 15 min), the supernatants were subject to ELISA and the pellets were used to prepare DNA.
Sqc-PCR.
We used sqc-PCR to determine the persistence of viral DNA in transduced cells at various times after injection of the virus into the brain. We co-amplified the pA and pIX regions of 50 ng of the viral DNA (282 bp) prepared from the striatum and the SN of injected brains and 3.4 pg of pA and pIX region of competitor (322 bp, plasmid pLTRIX-GDNF 10 ) with 1 mM of both the forward primer 5 0 -ACC ATT ATA AGC TGC AAT AAA CA-3 0 and the reverse primer 5 0 -ACT ACA TAA GAC CCC CAC CTT A-3 0 (Genset Corp) in 1 Â PCR buffer (Promega), 1.5 mM MgCl 2 (Promega), 200 mM dNTPs (Promega) and 1.5 U of Taq polymerase (Promega) in a final volume of 50 ml.
PCR consisted of 40 cycles of denaturation at 951C for 1 min, annealing at 561C for 1 min and extension at 721C for 1 min. The samples (5 ml) from each tube were then subjected to electrophoresis. The relative amount of each product was determined by densitometric scanning of ethidium bromide-stained gels (phospho-imager apparatus, Fujifilm, FLAG-2000, AIDA 2.43 software).
Behavioral analysis
The animals were tested for amphetamine-induced turning 1 week after viral injection. We injected rats displaying an amphetamine-induced contralateral turning of 0.05-0.1/min with 6-OHDA. After a 6-OHDAprovoked lesion, the rats were tested for amphetamineinduced turning at 2, 3, 5 and 11 weeks (corresponding to 3, 4, 6 and 12 weeks after the viral injection). Motor asymmetry was monitored in automated rotometer bowls (depth ¼ 34 cm, diameter ¼ 26 cm; Imetronic, Bordeaux, France) for 90 min after injection of D-amphetamine sulfate (Sigma, 5 mg/kg, i.p.). We recorded rotational behavior and calculated a net rotation asymmetry score for each test by subtracting contralateral turns from ipsilateral turns due to the lesion.
Histology
We used 10 animals from the Ad-NSE-GDNF group (NSE group) at each time point (4, 6 and 12 weeks) for immunohistochemical analysis. In the control groups, we analyzed five animals treated with empty adenovirus (EP group) or only lesioned with 6-OHDA (OHDA group) at each point.
Perfusion and tissue processing. Rats were deeply anaesthetized with T61 (Hoechst-Roussel) 4, 6 and 12 weeks after viral injection and then perfused with 0.9% NaCl followed by ice-cold 4% paraformaldehyde in PBS 2 h after amphetamine injection. Brains were removed and post-fixed by incubation in the same solution for 2 h at 41C and then transferred to 20% sucrose in PBS. Brains were frozen in dry-iced-cooled isopentane and stored at À801C until used. Frontal sections were cut at 14 mm intervals.
Histological analysis. Cryostat sections (14 mm) were incubated with 10% normal goat serum and 0.2% Triton (Sigma) in PBS for 30 min at room temperature and then incubated with a 1:500 dilution of rabbit anti-TH antibody (J Boy), rabbit anti-c-Fos antibody (sc-52, Santa Cruz Biotechnology, Tebu, le Perray en Yvelines, France), rabbit anti-GFAP antibody (Dako, Denmark), mouse anti-NeuN antibody (Chemicon international, CA, USA) or a 1:100 dilution of rabbit anti-GDNF antibody (Santa-Cruz Biotechnology), mouse NCL-GFAP-GA5 antibody (Tebu, le Perray en Yvelines, France), mouse CD4 or CD8 antibodies (Cedarlane, Canada) for 2 h. The sections were then incubated for 1 h with the appropriate biotinylated secondary antibodies (Vector Laboratories, Burlingame, CA, USA) directed against the species in which primary antibody was raised. The sections were then incubated with avidin-biotin-peroxidase complex for 1 h (ABC, Vector Laboratories, Burlingame, CA, USA). The reaction was visualized using 3,3-diaminobenzidine (DAB), SG (Vector Laboratories) or VIP (Vector Laboratories) as a chromogen. In some experiments, cryostat sections were incubated for 2 h with a mixture of polyclonal anti-GDNF and monoclonal anti-NeuN antibodies or polyclonal anti-GDNF and monoclonal anti-GFAP antibodies. The sections were then stained with Alexa Fluor 488 goat anti-rabbit (for GDNF) and Alexa Fluor 546 goat anti-mouse (for NeuN and GFAP) secondary antibodies (Invitrogen, Cergy-Pontoise, France).
Morphometric analysis
Nigral cell count. Only animals that were correctly injected either with the virus or with the 6-OHDA were included in our analyses. We ascertained this by following the tracks of the needles on cryostat sections. The trace of the needles was visualized by NeuN staining on tissue sections. The number of the FG-positive cells in the SN pars compacta was counted in images taken directly from fluorescent microscopy. The same sections were then stained with anti-TH antibody. We determined the number of TH immunoreactive cell bodies in the SN (excluding the ventral tegmental area) in every fifth serial section between the coordinates AP:À4.3, À5.3 and À5.8 mm from bregma. 10 We calculated the dopaminergic neuron survival as the percentage of TH immunoreactive cells or FG-positive cells counted in the SN on the lesion side to those in the contralateral SN (the average of three levels).
Striatal TH positive fiber innervation. All striatum images ( Figure 9a ) were taken with a camera (Nikon) and stored on CD-ROM using Intellicom software. For each animal, the whole cross-sectional area of the striatum and the deafferented region were outlined on the computer screen and the optical density was measured at three levels: AP: +1.7; AP: +1.2; AP: +0.2 relative to the bregma (four sections per level), using Aida 2.43 software. The intensity of TH staining was expressed as a percentage of the contralateral side.
Inflammation. The inflammation of the injected striatum was determined semiquantitatively on CD4/CD8-immunostained sections. The intensity of the staining was directly estimated under the microscope in four regions: at the injection sites (virus/6-OHDA), in the parenchyma, in the perivascular zones and in the cortical surface layers. Inflammation was scored as follows: (À) staining from non-injected animals, (7) very little staining, (+) little staining, (++) moderate staining, (+++) strong staining, (++++) very strong staining. Ten immunostained sections were examined for each brain. The results were expressed as the average estimated for each animal. The number of animals in which the treatment produced inflammation is reported in Table 3 .
Statistical analysis
All values were expressed as the mean7s.e.m. (standard error of the mean). Differences between groups were analyzed by using one-way analysis of variance (ANOVA) followed, when significant (Po0.05), by Student's t-test.
